YU69000A - Antitela za cd23, njihovi derivati i njihove terapeutske upotrebe - Google Patents
Antitela za cd23, njihovi derivati i njihove terapeutske upotrebeInfo
- Publication number
- YU69000A YU69000A YU69000A YU69000A YU69000A YU 69000 A YU69000 A YU 69000A YU 69000 A YU69000 A YU 69000A YU 69000 A YU69000 A YU 69000A YU 69000 A YU69000 A YU 69000A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- antibodies
- derivatives
- therapeutic uses
- fcεrii
- bind
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Ovaj pronalazak se odnosi na antitela koja se vezuju na molekul CD23 (FCεRII) tip II, naročito izmenjena antitela koja sadrže antitela koja se vezuju na molekul CD23 (FCεRII) tip II, karakteristična po konstanti afiniteta jednakoj ili većoj od 1x103 (KaMo1-1), dobijanje takvih antitela, farmaceutske formulacije koje sadrže takva antitela i njihovu upotrebu u terapiji posebno u tretmanu autoimunih i inflamatornih poremećaja.[The invention relates to antibodies which bind to the CD23 (FCεRII) type II molecule particularly altered antibodies including antibodies which bind to the CD23 (FCεRII) type II molecule characterised by an affinity constant equal to or greater than 1x109 Ka Mo1-1, the preparation of such antibodies, pharmaceutical compositions which contain such antibodies and their use in therapy particularly in the treatment of autoimmune and inflammatory disorders.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9809839.5A GB9809839D0 (en) | 1998-05-09 | 1998-05-09 | Antibody |
Publications (1)
Publication Number | Publication Date |
---|---|
YU69000A true YU69000A (sh) | 2003-08-29 |
Family
ID=10831668
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
YU69000A YU69000A (sh) | 1998-05-09 | 1999-05-07 | Antitela za cd23, njihovi derivati i njihove terapeutske upotrebe |
Country Status (25)
Country | Link |
---|---|
US (1) | US7008623B1 (sh) |
EP (1) | EP1076701A1 (sh) |
JP (1) | JP2002514421A (sh) |
KR (1) | KR20010043470A (sh) |
CN (1) | CN1308676A (sh) |
AP (1) | AP1547A (sh) |
AU (1) | AU763491B2 (sh) |
BR (1) | BR9910327A (sh) |
CA (1) | CA2328606A1 (sh) |
EA (1) | EA200001041A1 (sh) |
EE (1) | EE200000658A (sh) |
GB (1) | GB9809839D0 (sh) |
HR (1) | HRP20000762A2 (sh) |
HU (1) | HUP0102005A3 (sh) |
ID (1) | ID28088A (sh) |
IL (1) | IL139384A0 (sh) |
IS (1) | IS5696A (sh) |
NO (1) | NO20005632L (sh) |
NZ (1) | NZ507879A (sh) |
PL (1) | PL344019A1 (sh) |
SK (1) | SK16762000A3 (sh) |
TR (1) | TR200003281T2 (sh) |
WO (1) | WO1999058679A1 (sh) |
YU (1) | YU69000A (sh) |
ZA (1) | ZA200006312B (sh) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6696550B2 (en) | 1998-07-23 | 2004-02-24 | Millennium Pharmaceuticals, Inc. | Humanized anti-CCR2 antibodies and methods of use therefor |
AU1174702A (en) | 2000-10-13 | 2002-04-22 | Biogen Inc | Humanized anti-lt-beta-r antibodies |
US20040151721A1 (en) | 2001-10-19 | 2004-08-05 | O'keefe Theresa | Humanized anti-CCR2 antibodies and methods of use therefor |
WO2004002431A2 (en) * | 2002-07-01 | 2004-01-08 | Biogen, Inc. | Humanized anti-lymphotoyin beta receptor antibodies |
TWI323265B (en) | 2002-08-06 | 2010-04-11 | Glaxo Group Ltd | Antibodies |
GB0306309D0 (en) | 2003-03-19 | 2003-04-23 | Glaxo Group Ltd | Method of treatment |
US7700097B2 (en) | 2003-06-27 | 2010-04-20 | Biogen Idec Ma Inc. | Purification and preferential synthesis of binding molecules |
CA2434668A1 (en) | 2003-07-04 | 2005-01-04 | Laurence Mulard | Novel approach to design glycopeptides based on o-specific polysaccharide of shigella flexneri serotype 2a |
AU2003300896A1 (en) * | 2003-12-10 | 2005-07-14 | Millennium Pharmaceuticals, Inc. | Humanized anti-ccr2 antibodies and methods of use |
US7435799B2 (en) * | 2004-01-08 | 2008-10-14 | Applied Molecular Evolution | TNF-α binding molecules |
JP2007530588A (ja) | 2004-03-23 | 2007-11-01 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | レセプターカップリング剤およびその治療用途 |
WO2006039470A2 (en) * | 2004-09-29 | 2006-04-13 | Centocor, Inc. | Anti- amyloid antibodies, compositions, methods and uses |
WO2006074399A2 (en) | 2005-01-05 | 2006-07-13 | Biogen Idec Ma Inc. | Multispecific binding molecules comprising connecting peptides |
DK1957106T4 (da) | 2005-11-14 | 2019-10-28 | Teva Pharmaceuticals Int Gmbh | Antagonist-antistoffer, der er rettet mod calcitonin-gen-relateret peptid og fremgangsmåder til anvendelse af disse |
GB0525662D0 (en) | 2005-12-16 | 2006-01-25 | Glaxo Group Ltd | Immunoglobulins |
US7680868B2 (en) * | 2005-12-20 | 2010-03-16 | Roche Molecular Systems, Inc. | PCR elbow determination by use of a double sigmoid function curve fit with the Levenburg-Marquardt algorithm and normalization |
EP1804172B1 (en) * | 2005-12-20 | 2021-08-11 | Roche Diagnostics GmbH | PCR elbow determination using curvature analysis of a double sigmoid |
US20090155255A1 (en) * | 2007-09-27 | 2009-06-18 | Biogen Idec Ma Inc. | Cd23 binding molecules and methods of use thereof |
ES2614284T3 (es) | 2007-11-30 | 2017-05-30 | Glaxo Group Limited | Construcciones de unión a antígenos |
ES2689322T3 (es) | 2008-03-04 | 2018-11-13 | Teva Pharmaceuticals International Gmbh | Métodos para tratar el dolor crónico |
TW201012489A (en) | 2008-05-06 | 2010-04-01 | Glaxo Group Ltd | Encapsulation of biologically active agents |
JP2012518398A (ja) | 2009-02-24 | 2012-08-16 | グラクソ グループ リミテッド | 抗原結合性構築物 |
EP2401296A1 (en) | 2009-02-24 | 2012-01-04 | Glaxo Group Limited | Multivalent and/or multispecific rankl-binding constructs |
CA2753332A1 (en) | 2009-02-24 | 2010-09-02 | Glaxo Group Limited | Antigen-binding constructs |
US20120128689A1 (en) | 2009-04-01 | 2012-05-24 | Glaxo Group Limited | Anti-il-23 immunoglobulins |
WO2010122090A1 (en) | 2009-04-24 | 2010-10-28 | Glaxo Group Limited | Fgfr1c antibody combinations |
US8623366B2 (en) | 2009-08-28 | 2014-01-07 | Labrys Biologics, Inc. | Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide |
FR2957598B1 (fr) | 2010-03-17 | 2015-12-04 | Lfb Biotechnologies | Nouveau peptide signal, et son utilisation pour la production de proteines recombinantes |
SG10201500388PA (en) | 2010-11-23 | 2015-03-30 | Glaxo Group Ltd | Antigen binding proteins to oncostatin m (osm) |
MX2013005847A (es) | 2010-11-24 | 2013-12-12 | Glaxo Group Ltd | Proteinas de union a antigeno multiespecificas que eligen como blanco a hgf. |
US8974782B2 (en) | 2011-02-07 | 2015-03-10 | Glaxo Group Limited | Treatment of stroke comprising anti-MAG antibodies |
EP3415531B1 (en) | 2011-05-27 | 2023-09-06 | Glaxo Group Limited | Bcma (cd269/tnfrsf17) - binding proteins |
WO2014029752A1 (en) | 2012-08-22 | 2014-02-27 | Glaxo Group Limited | Anti lrp6 antibodies |
US10176293B2 (en) | 2012-10-02 | 2019-01-08 | Roche Molecular Systems, Inc. | Universal method to determine real-time PCR cycle threshold values |
CN105209494B (zh) | 2013-03-15 | 2019-04-09 | 葛兰素史克知识产权开发有限公司 | 抗lag-3结合蛋白 |
JP6440036B2 (ja) * | 2013-07-10 | 2018-12-19 | オンコノックス エーピーエス | 抗β2−グリコプロテインI抗体及びその治療的用法 |
KR20220130822A (ko) | 2014-03-21 | 2022-09-27 | 테바 파마슈티컬스 인터내셔널 게엠베하 | 칼시토닌 유전자-관련 펩티드에 대한 길항제 항체 및 그의 사용 방법 |
US10556945B2 (en) | 2014-03-21 | 2020-02-11 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
EP3344654B1 (en) | 2015-09-02 | 2020-10-21 | Immutep S.A.S. | Anti-lag-3 antibodies |
US10479827B2 (en) * | 2016-05-31 | 2019-11-19 | Sysmex Corporation | Monoclonal antibody reacting with glycopeptide, and use thereof |
JP6935184B2 (ja) * | 2016-05-31 | 2021-09-15 | シスメックス株式会社 | 糖ペプチドと反応するモノクローナル抗体およびその用途 |
EP3471754A1 (en) | 2016-06-20 | 2019-04-24 | Kymab Limited | Anti-pd-l1 antibodies |
EP3515937A1 (en) | 2016-09-23 | 2019-07-31 | Teva Pharmaceuticals International GmbH | Treating refractory migraine |
WO2020261097A1 (en) | 2019-06-26 | 2020-12-30 | Glaxosmithkline Intellectual Property Development Limited | Il1rap binding proteins |
CN112552403A (zh) * | 2020-12-25 | 2021-03-26 | 南京英瀚斯生物科技有限公司 | 一种人源抗人CD23抗体的Fab片段、药物组合物及其应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE922437A1 (en) * | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
DK1266965T3 (da) * | 1991-07-25 | 2006-09-25 | Biogen Idec Inc | Rekombinante antistoffer til human terapi |
WO1996012741A1 (en) * | 1994-10-25 | 1996-05-02 | Glaxo Group Limited | Binding agents to cd23 |
US6011138A (en) * | 1997-02-20 | 2000-01-04 | Idec Pharmaceuticals Corporation | Gamma-1 anti-human CD23 monoclonal antibodies |
-
1998
- 1998-05-09 GB GBGB9809839.5A patent/GB9809839D0/en not_active Ceased
-
1999
- 1999-05-07 EE EEP200000658A patent/EE200000658A/xx unknown
- 1999-05-07 JP JP2000548470A patent/JP2002514421A/ja not_active Ceased
- 1999-05-07 SK SK1676-2000A patent/SK16762000A3/sk unknown
- 1999-05-07 HU HU0102005A patent/HUP0102005A3/hu unknown
- 1999-05-07 AP APAP/P/2000/001983A patent/AP1547A/en active
- 1999-05-07 PL PL99344019A patent/PL344019A1/xx unknown
- 1999-05-07 CN CN99808452A patent/CN1308676A/zh active Pending
- 1999-05-07 YU YU69000A patent/YU69000A/sh unknown
- 1999-05-07 KR KR1020007012530A patent/KR20010043470A/ko not_active Application Discontinuation
- 1999-05-07 IL IL13938499A patent/IL139384A0/xx unknown
- 1999-05-07 AU AU38367/99A patent/AU763491B2/en not_active Ceased
- 1999-05-07 EA EA200001041A patent/EA200001041A1/ru unknown
- 1999-05-07 WO PCT/GB1999/001434 patent/WO1999058679A1/en not_active Application Discontinuation
- 1999-05-07 TR TR2000/03281T patent/TR200003281T2/xx unknown
- 1999-05-07 NZ NZ507879A patent/NZ507879A/xx unknown
- 1999-05-07 ID IDW20002573A patent/ID28088A/id unknown
- 1999-05-07 CA CA002328606A patent/CA2328606A1/en not_active Abandoned
- 1999-05-07 EP EP99920991A patent/EP1076701A1/en not_active Withdrawn
- 1999-05-07 BR BR9910327-3A patent/BR9910327A/pt not_active Application Discontinuation
- 1999-05-07 US US09/674,716 patent/US7008623B1/en not_active Expired - Fee Related
-
2000
- 2000-10-31 IS IS5696A patent/IS5696A/is unknown
- 2000-11-03 ZA ZA200006312A patent/ZA200006312B/xx unknown
- 2000-11-08 NO NO20005632A patent/NO20005632L/no not_active Application Discontinuation
- 2000-11-09 HR HR20000762A patent/HRP20000762A2/hr not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
NO20005632L (no) | 2001-01-08 |
PL344019A1 (en) | 2001-09-24 |
HRP20000762A2 (en) | 2001-06-30 |
IL139384A0 (en) | 2001-11-25 |
SK16762000A3 (sk) | 2001-07-10 |
CA2328606A1 (en) | 1999-11-18 |
WO1999058679A1 (en) | 1999-11-18 |
NO20005632D0 (no) | 2000-11-08 |
EP1076701A1 (en) | 2001-02-21 |
EA200001041A1 (ru) | 2001-06-25 |
ZA200006312B (en) | 2003-02-26 |
AP1547A (en) | 2006-01-13 |
ID28088A (id) | 2001-05-03 |
BR9910327A (pt) | 2001-01-30 |
KR20010043470A (ko) | 2001-05-25 |
AP2000001983A0 (en) | 2000-12-31 |
CN1308676A (zh) | 2001-08-15 |
NZ507879A (en) | 2004-02-27 |
HUP0102005A3 (en) | 2003-10-28 |
GB9809839D0 (en) | 1998-07-08 |
JP2002514421A (ja) | 2002-05-21 |
EE200000658A (et) | 2002-04-15 |
AU763491B2 (en) | 2003-07-24 |
AU3836799A (en) | 1999-11-29 |
TR200003281T2 (tr) | 2001-03-21 |
HUP0102005A2 (hu) | 2001-10-28 |
US7008623B1 (en) | 2006-03-07 |
IS5696A (is) | 2000-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
YU69000A (sh) | Antitela za cd23, njihovi derivati i njihove terapeutske upotrebe | |
BG109311A (en) | PHARMACEUTICAL COMPOSITION, INCLUDING HUMAN ANTIBODIES CONNECTING HUMAN TNFAL, AND HIS APPLICATION | |
DE60028970D1 (de) | An her2 bindende peptidverbindungen | |
NZ324500A (en) | Humanized antibodies to human gp39, compositions containing and therapeutic use thereof | |
SI1465626T1 (sl) | Farmacevtski sestavki (komplet), ki obsegajo dihidropiridionske spojine in imunoregulacijsko (ali protivnetno) sredstvo, in njihove uporabe | |
YU34196A (sh) | Peptidi i jedinjenja koja se vezuju za receptor | |
AP2004003069A0 (en) | 3-beta-d-ribofuranosynthiazolo [4-5-d] pyridimine nucleosides and uses thereof. | |
ATE427353T1 (de) | Heregulin varianten | |
MY129189A (en) | Prostaglandin agonists and their use to treat bone disorders | |
EP0797999A3 (en) | Formulations of obesity protein | |
AU5186799A (en) | Peptides of il-2 and derivatives thereof and their use as therapeutic agents | |
BG102250A (en) | The use of marigold-extracted glycosides for the treatment of psoriasis | |
DE69911401D1 (en) | Immunoregulator | |
WO2002026781A3 (en) | Ige receptor antagonists | |
AU7216498A (en) | Inhibitors of the urokinase receptor | |
ZA965891B (en) | Tnf receptor and steroid hormone in a combined therapy | |
ZA961419B (en) | Human DNase I variants. | |
MX9706429A (es) | Variantes de dnasa i humana. | |
UA83988C2 (ru) | Моноклональное антидвойное интегриновое антитело, которое специфически связывает человеческие интегрины альфа v бета 3 и альфа v бета 5, фармацевтическая композиция, которая его содержит, и их применение в терапии |